Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects

Status Completed

Clinical Trial Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the efficacy of 4 treatment regimens of Cat-PAD in cat allergic subjects following challenge to cat allergen in an environmental exposure chamber (EEC).

Clinical Trial Description

This study is designed as a multicentre, randomised, double-blind, placebo-controlled study of 4 treatment regimens in up to 120 cat allergic subjects. A total of 24 subjects will be randomised into each treatment group. Each subject will undergo screening up to 4 weeks before treatment. Baseline challenge will consist of exposure to cat allergen for 3 hours in an EEC on 4 visits on successive days a week before the first administration of Cat-PAD or placebo. Treatment will be administered as intradermal injections into the flexor surface of alternate forearms. There are 5 treatment regimens involving administration of Cat-PAD or placebo. Post-treatment challenge (PTC) will consist of exposure to cat allergen for 3 hours in an EEC on 4 visits on successive days 18 weeks after the first administration of study medication. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00729508
Study type	Interventional
Source	Circassia Limited
Contact
Status	Completed
Phase	Phase 2
Start date	August 2008
Completion date	May 2009

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02959073` - Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients	N/A
Completed	`NCT00987909` - Exposure Chamber Trial With Cat Immunotherapy	Phase 2
Completed	`NCT01383590` - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis	Phase 1
Completed	`NCT01383603` - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis	Phase 1
Completed	`NCT01003301` - The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge	Phase 2
Completed	`NCT02311413` - A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy	Phase 2
Completed	`NCT02237196` - Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy	Phase 1/Phase 2
Completed	`NCT02399579` - Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients	N/A
Terminated	`NCT01292070` - Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy	Phase 0
Completed	`NCT00867906` - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma	Phase 2
Completed	`NCT04435678` - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens	N/A
Completed	`NCT01033344` - Cat-PAD Exposure Chamber Study	Phase 2
Completed	`NCT00685711` - Safety of Cat-PAD in Cat Allergic Subjects	Phase 1/Phase 2
Completed	`NCT02040844` - Phase III Cat-PAD Follow-on Study	Phase 3
Completed	`NCT01604018` - An Optional Two Year Follow Up Study to Study CP005A	N/A
Completed	`NCT01272323` - Cat-PAD Follow on Study	N/A
Completed	`NCT03838731` - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge	Phase 2
Recruiting	`NCT05331170` - Viral Mucosal Reprogramming	Phase 2